$67.15 +1.98 (%) Endo International plc - NASDAQ

Sep. 17, 2014 | 10:10 AM

Partner Headlines

  1. Morning Market Movers

    Benzinga | Sep. 17, 2014 | 09:38AM EST
  2. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 17, 2014 | 08:08AM EST
  3. Stocks To Watch For September 17, 2014

    Benzinga | Sep. 17, 2014 | 04:08AM EST
  4. Benzinga's M&A Chatter for Tuesday September 16, 2014

    Benzinga | Sep. 16, 2014 | 19:29PM EST
  5. ENDO INT'L

    IBD | Sep. 16, 2014 | 18:49PM EST
  6. Auxilium Pharmaceuticals, Inc. Gets $2.2 Billion Unsolicited Bid

    Benzinga | Sep. 16, 2014 | 17:42PM EST
  7. UPDATE: Endo Offers to Buy Auxilium Pharma at $28.10/Share in Cash, Stock

    Benzinga | Sep. 16, 2014 | 16:48PM EST
  8. Benzinga's Top Initiations

    Benzinga | Sep. 2, 2014 | 09:16AM EST
  9. RBC Capital Initiates Endo Health At Outperform

    Benzinga | Sep. 2, 2014 | 07:42AM EST
  10. Endo's Paladin Labs Reports Canadian Introduction Of Veregen

    Benzinga | Jul. 16, 2014 | 07:40AM EST
  11. Stock Futures Sag Early Monday; King Digital Leans Higher

    IBD | Jul. 7, 2014 | 08:59AM EST
  12. Benzinga's M&A Chatter for Tuesday June 24, 2014

    Benzinga | Jun. 24, 2014 | 17:53PM EST
  13. Wells Fargo Initiates Coverage On The Pharmaceutical Space

    Benzinga | Jun. 11, 2014 | 11:36AM EST
  14. UPDATE: Morgan Stanley Upgrades Endo International PLC On Attractive Risk-Reward

    Benzinga | May. 2, 2014 | 10:14AM EST
  15. Endo profit tops despite charge

    IBD | May. 1, 2014 | 18:51PM EST
  16. Sterne Agee Sees Good Things Ahead for Endo International PLC

    Benzinga | May. 1, 2014 | 08:10AM EST
  17. Earnings Scheduled For May 1, 2014

    Benzinga | May. 1, 2014 | 05:36AM EST
  18. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD | Apr. 30, 2014 | 17:28PM EST
  19. Endo Reaches $830M Settlement on Majority of AMS Litigation Cases

    Benzinga | Apr. 30, 2014 | 16:32PM EST
  20. Actavis Q1 Earnings Beat On Generic Cymbalta Surprise

    IBD | Apr. 30, 2014 | 11:10AM EST
  21. Endo to Acquire Grupo Farmaceutico, No Terms Disclosed

    Benzinga | Apr. 29, 2014 | 08:32AM EST
  22. Morning Market Movers

    Benzinga | Apr. 24, 2014 | 09:42AM EST
  23. Benzinga's Top #PreMarket Gainers

    Benzinga | Apr. 24, 2014 | 08:11AM EST
  24. Zogenix Announces Sale of SUMAVEL DosePro Migraine Therapy to Endo International for $85M, Up to $20M Milestone Payments

    Benzinga | Apr. 24, 2014 | 07:31AM EST
  25. Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium

    GuruFocus | Apr. 23, 2014 | 16:46PM EST
  26. Mylan Says Judge Has Enforced Settlement Deal Between Mylan, Endo Related to Generic FROVA

    Benzinga | Apr. 11, 2014 | 07:31AM EST
  27. Morgan Stanley Sees Possible Upside Source for Endo International PLC

    Benzinga | Apr. 10, 2014 | 09:58AM EST
  28. Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane in Canada

    Benzinga | Apr. 10, 2014 | 08:05AM EST
  29. Meda Rejects Mylan's Bid

    IBD | Apr. 4, 2014 | 18:46PM EST
  30. Mylan Rejected In Bid To Acquire Sweden's Meda

    IBD | Apr. 4, 2014 | 12:27PM EST
  31. Market Wrap For March 6: Investors Find Positives In Jobless Claims

    Benzinga | Mar. 6, 2014 | 17:06PM EST
  32. Morgan Stanley Updates Estimates On Endo Health Solutions

    Benzinga | Mar. 3, 2014 | 10:07AM EST
  33. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga | Feb. 28, 2014 | 16:53PM EST
  34. Earnings Scheduled For February 28, 2014

    Benzinga | Feb. 28, 2014 | 04:58AM EST
  35. Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio

    Benzinga | Feb. 28, 2014 | 04:30AM EST
  36. Stocks End Higher; MercadoLibre Jumps After Hours

    IBD | Feb. 27, 2014 | 16:58PM EST
  37. Actavis Q4 Beats Street; Guidance Affirmed For Now

    IBD | Feb. 20, 2014 | 11:21AM EST
  38. Endo Confirms Court Upholds FROVA Patent

    Benzinga | Jan. 29, 2014 | 16:41PM EST
  39. Top Gainers After Hours

    Benzinga | Jan. 23, 2014 | 17:13PM EST
  40. UPDATE: Endo and BioDelivery Sciences Announce Positive Top-Line Results from the Phase III Clinical Trial of BEMA Buprenorphine in Opioid Naive Patients with Chronic Pain

    Benzinga | Jan. 23, 2014 | 16:31PM EST
  41. Benzinga's M&A Chatter for Tuesday January 21, 2014

    Benzinga | Jan. 21, 2014 | 18:06PM EST
  42. Drug Mergers Queuing Up

    IBD | Jan. 8, 2014 | 18:42PM EST
  43. Stocks End Mixed; Macy's Up After Hours, To Cut Jobs

    IBD | Jan. 8, 2014 | 16:53PM EST
  44. Market Wrap For January 8: Fed Minutes Released

    Benzinga | Jan. 8, 2014 | 16:39PM EST
  45. Stocks Mixed As Chips Buoy Nasdaq; Endo Health Breaks Out

    IBD | Jan. 8, 2014 | 14:56PM EST
  46. Forest Buying Aptalis; Teva Bids For NuPathe Vs. Endo

    IBD | Jan. 8, 2014 | 11:24AM EST
  47. Endo Health Solutions

    IBD | Jan. 2, 2014 | 18:49PM EST
  48. Stocks Near Day's Lows; SunPower Heats Up

    IBD | Jan. 2, 2014 | 13:29PM EST
  49. Endo Health Downgraded On Weak Zecuity Outlook

    IBD | Jan. 2, 2014 | 10:54AM EST
  50. Endo Announces Early Termination of HSR Act Waiting Period in Connection with Its Proposed Acquisition of Paladin Labs

    Benzinga | Dec. 19, 2013 | 10:14AM EST
Trading Center